Interstitial Lung DiseaseNCT05916404
Effects of Upper Extremity Aerobic Exercise Training in Patients With Interstitial Lung Disease
A study testing Upper extremity high-intensity interval aerobic exercise training in people with Interstitial Lung Disease, run by Gazi University at 1 site in Turkey (Türkiye).
Trial summary
Severe dyspnea, cough, fatigue, restrictive type ventilation disorder, decreased pulmonary function, impaired gas exchange, decreased cardiovascular function and exercise intolerance are frequently encountered findings in patients with interstitial lung disease. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Interstitial Lung Disease
- What is being tested?
- Upper extremity high-intensity interval aerobic exercise training
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 3 Jul 2023to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with ILD according to ATS/ERS criteria,
- Aged between 18-75 years,
- No pulmonary infection during the last month,
- Patients who volunteer to participate in the study
Who cannot join
- Patients with,
- Body mass index >35 kg/m2,
- An acute pulmonary exacerbation within the last 4 weeks, have an acute upper or lower respiratory tract infection,
- Presence of obstructive pulmonary disease,
- Serious neurological, neuromuscular, orthopedic, or other diseases affecting physical functions,
- Participated in a planned exercise program within the last three months,
Show all 11Show fewer
- Cognitive impairment that causes them to have difficulty understanding and following exercise test instructions,
- Contraindications for exercise testing and/or exercise training according to the American College of Sports Medicine
- Cancer, renal or hepatic diseases,
- Aortic stenosis, complex arrhythmia, with aortic aneurysm,
- Uncontrolled hypertension, diabetes mellitus, heart failure, arrhythmia and serious cardiovascular disease
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Unit
Ankara, Çankaya, 06490
About this study
Official title: Investigation of the Effects of Upper Extremity Aerobic Exercise Training on Oxygen Consumption, Muscle Oxygenation and Physical Activity in Patients With Interstitial Lung Disease
Severe dyspnea, cough, fatigue, restrictive type ventilation disorder, decreased pulmonary function, impaired gas exchange, decreased cardiovascular function and exercise intolerance are frequently encountered findings in patients with interstitial lung disease. It was demonstrated exercise training has beneficial effects in patients with interstitial lung disease. However, no study investigated the effects of upper extremity aerobic exercise training on outcomes in patients with interstitial lung disease.
Read the detailed description
Interstitial lung diseases (ILD) are a heterogeneous group of diseases that cause significant mortality and morbidity worldwide. As a result of the chronic inflammatory process in this disease, structural and mechanical pulmonary disorders develop, which are considered the main causes of deterioration in cardiopulmonary functions. Interstitial lung patients have a decrease in both static and dynamic lung volumes and carbon monoxide diffusing capacity (DLCO). As a result of this pathological mechanism, effort dyspnea and an increase in exercise intolerance occur. Therefore, individuals with ILD tend to avoid activities that increase shortness of breath, resulting in decreased physical activity levels and an increased sedentary lifestyle. Individuals whose functional exercise capacities are also limited due to this vicious circle become more dependent in their daily living activities. In addition, peripheral muscle dysfunction is another important factor that causes exercise intolerance in individuals with all chronic lung diseases, including ILD. One of the most important mechanisms triggering peripheral muscle dysfunction in ILD is hypoxia which develops with desaturation. Hypoxia, which causes an increase in oxidative stress, is one of the factors that can cause muscle dysfunction. It has been reported that upper extremity exercise capacity and functional performance are low in individuals with advanced ILD, and it has been stated that upper extremity exercise training may be beneficial in these patients.
However, the effects of upper extremity aerobic exercise training have not been investigated in the literature in patients with ILD. In this context, the primary aim of our study is to investigate the effects of upper extremity interval aerobic exercise training applied to patients with ILD on oxygen consumption, muscle oxygenation, and physical activity level. The secondary aim of the study is to determine the effects of this training on upper extremity functional exercise capacity, respiratory functions, pulmonary diffusion capacity, respiratory and peripheral muscle strength, inspiratory muscle endurance, dyspnea, fatigue, quality of life, sleep quality, anxiety, and depression. For this purpose, our study was planned as a randomized, controlled, three-blind (investigators, patient, and analyzer) prospective study. According to the block randomization result, at least 21 patients with a diagnosis of ILD will be included in the training and control groups.
The training group will be given upper extremity interval aerobic exercise training with arm ergometer for 30-45 minutes 3 days a week for 6 weeks, and the control group will not be given any training during the study. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
All assessments will be completed in two days, before and after six weeks of training.
- Conditions
- Interstitial Lung Disease
- Being tested
- Upper extremity high-intensity interval aerobic exercise training, Control Group
- Keywords
- Interstitial Lung Disease, Upper Extremity, Aerobic Exercise, Oxygen Consumption, Physical Activity
- Medical subject headings
- Lung Diseases, Interstitial, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Upper extremity high-intensity interval aerobic exercise trainingOther
High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.
In case of desaturation (<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient.
Control GroupOther
The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
| Study group | Role | What they receive |
|---|---|---|
| Training Group | Experimental | The training group will receive upper extremity high-intensity interval aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks. Receives: Other: Upper extremity high-intensity interval aerobic exercise training |
| Control Group | Sham comparator | The control group will not be given any training for 6 weeks during the study period. Receives: Other: Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oxygen consumption
Maximal exercise capacity will be assessed with symptom limited cardiopulmonary exercise test on a treadmill at a progressively increasing speed and grade. Oxygen consumption will be measured during the test.
Measured: through study completion, an average of 2 year
Muscle oxygenation
Before the cardiopulmonary exercise test and the 6-minute pegboard and ring test (6-PBRT), during and after the tests the muscle oxygenation will be measured by using a near-infrared spectroscopy device. Oxygenation of the quadriceps muscle during the cardiopulmonary exercise test, and deltoid muscle during the 6-PBRT will be evaluated. For this purpose, the sensor will be placed at the midpoint of the dominant side muscles.
Measured: through study completion, an average of 2 year
Physical activity level
Physical activity level will be evaluated with a multi-sensor activity device. Multisensor metabolic holter device by detecting the three-dimensional movements of patients; It provides data on total energy expenditure (joules/day), active energy expenditure (joules/day), physical activity duration (min/day), average MET (MET/day), number of steps (steps/day), time spent lying down (min/day). The device will be attached to the non-dominant arms of the patients, and they will be told to wear it for 5 consecutive days, remove the device only during the bath, and reinsert it in the same area after the bath. The average of the parameters of the current four days will be taken and analyzed with the "BodyMedia SenseWear® 7.0 Software" program using the age, gender, body weight and height information of the patients.
Measured: through study completion, an average of 2 year
Secondary outcomes (19)
Respiratory muscle strength
Respiratory muscle strength will be assessed with mouth pressure device. Maximal inspiratory and expiratory pressure (MIP and MEP) will be measured during the test. This values is expressed in centimeters of water (cmH2O) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Peripheral muscle strength
Shoulder flexion and abduction muscles and Quadriceps femoris muscle strength will be measured by using a hand-held dynamometer. This values is expressed in Newtons (N) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Upper extremity functional exercise capacity
6-minute pegboard and ring test will be performed to assess upper extremity functional exercise capacity. As a result of the test, the total number of ring inserted end of six minutes will be recorded in pieces. It will be expressed as a percentage (%) of the expected value. The presence of any symptoms during the test, supplemental oxygen support, and assistive device usage status will be recorded.
Measured: through study completion, an average of 2 year
Dyspnea perception
"Modified Medical Research Council" dyspnea scale will be used to question dyspnea perception during activities. This scale is a 5-point scale based on rating various physical activities that increase shortness of breath. The lowest and highest values on this scale are as follows: Level 0 "No shortness of breath except strenuous exercise" and level 4 "Too breathless to leave the house or breathless while dressing or undressing."
The London Chest Activity of Daily Living scale (Turkish version) will be used to evaluate dyspnea perception during activities of daily living in patients. The scale has a total of 4 subheadings and a total of 15 items, including personal care (4 items), household chores (6 items), physical (2 items) and leisure (3 items). Each item is scored on a scale of 0-5 points. Sub-title score and total score are evaluated. The total score is a maximum of 75. As the overall score increases, so does the dependence on activities of daily living.
Measured: through study completion, an average of 2 year
Fatigue
Fatigue will be assessed with Fatigue Severity Scale (Turkish version). This scale includes 9 items and each item scores from 1 (strong disagreement) to 7 (strong agreement) point. Fatigue Severity Scale total score is calculates by deriving an arithmetic mean. Cut-score of over 4 means significant fatigue and higher score indicates more severe fatigue.
Measured: through study completion, an average of 2 year
Life Quality
Quality of life will be assessed with Saint George Respiratory Questionnaire (SGRQ) (Turkish version). This questionnaire is a questionnaire used to evaluate the quality of life in respiratory diseases. The questionnaire consists of 3 parts: symptoms (8 items), activities (16 items), effects of the disease (26 items) and a total of 50 items: 3 parts of the test are scored separately. Then the total score is obtained. The total score ranges from 0-100. A score of zero is normal, while a score of 100 represents maximum disability. As the total score increases, it indicates that poor quality of life. In this questionnaire, a change of 4 points with treatment is considered significant.
Measured: through study completion, an average of 2 year
Sleep Quality
The Pittsburgh Sleep Quality Index (Turkish version) will be used to evaluate the sleep quality of the patients. 19 of the questions in the index, which consists of a total of 24 questions, are questions that the individual answers by evaluating himself/herself. The remaining 5 questions are answered by the individual's bed partner or roommate, if any. The questionnaire includes questions asked under 7 main headings: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medication, and daytime functions. Each of these 7 main headings is first evaluated in its own right. The scores of the 7 components are then summed up. If the total score is above 5 points, it is considered bad sleep.
Measured: through study completion, an average of 2 year
Anxiety and Depression
Hospital Anxiety and Depression Scale (Turkish version) will be used to evaluate the anxiety and depression levels of the patients. It consists of two subdivisions: Anxiety (HAD-A) and depression (HAD-D). 7 questions consisting of odd numbers (questions 1, 3, 5, 7, 9, 11, 13) measure anxiety, and 7 questions consisting of even numbers (questions 2, 4, 6, 8, 10, 12, 14) measure depression. For the answers to each question, a score of 0-3 is made in the form of a quadruple likert. The lowest score that can be obtained from both subscales is 0 and the highest score is 21. As the score increases, the severity of anxiety and depression increases. 0-7 is considered normal, 8-10 is borderline, 11 and above is considered abnormal. 10 points and above for anxiety and 8 points and above for depression are considered significant.
Measured: through study completion, an average of 2 year
Modified Borg scale
The assessment of dyspnea and fatigue perception in all patients at rest, during, and after exercise training will be performed with the Modified Borg scale. In addition, the perception of dyspnea and fatigue before, during, and after the cardiopulmonary exercise test and 6 minutes of pegboard and ring test will be evaluated with the Modified Borg scale. The modified Borg scale is a subjective scale and scores patients' dyspnea at rest and/or during activity on a scale of 0-10. The lowest score of 0 (zero) indicates "not at all" and the highest score of 10 (ten) indicates "very very serious" shortness of breath or fatigue.
Measured: through study completion, an average of 2 year
Energy expenditure
Energy expenditure during the cardiopulmonary exercise test and 6-minute pegboard and ring test will be evaluated with a multi-sensor activity device. It is expressed in joules.
Measured: through study completion, an average of 2 year
Inspiratory muscle endurance
Inspiratory muscle endurance will be measured incremental threshold loading test, in which patients started an initial load of 30% of maximal inspiratory pressure and test load will be increased with among 10% of maximal inspiratory pressure every 2 minutes.
Measured: through study completion, an average of 2 year
Forced expiratory volume exhaled in the first second (FEV1)
Forced expiratory volume exhaled in the first second (FEV1) will be evaluated by using spirometry. FEV1 is the expiratory volume in the first second of an FVC maneuver which is the volume delivered during an expiration made as forcefully and completely as possible starting from full inspiration. FEV1 is expressed in liters (L) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Forced vital capacity (FVC)
Forced vital capacity (FVC) will be evaluated by using spirometry. FVC is the volume delivered during an expiration made as forcefully and completely as possible starting from full inspiration. It is expressed in liters (L) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
FEV1/FVC ratio
This value is the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC). FEV1/FVC ratio will be evaluated by using spirometry. It is expressed as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Peak expiratory flow (PEF)
Peak expiratory flow (PEF) is the highest flow achieved from a maximum forced expiratory maneuver started without hesitation from a position of maximal lung inflation. PEF will be evaluated by using spirometry. It is expressed in liters (L) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Forced mid-expiratory flow rate (FEF25-75%)
Forced mid-expiratory flow rate (FEF25-75%) will be evaluated by using spirometry. FEF25-75% value is forced expiratory flow over the middle one-half of the FVC. It refers the average flow from the point at which 25% of the FVC has been exhaled to the point at which 75% of the FVC has been exhaled. It is expressed in liters (L) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Diffusion capacity for carbon monoxide (DLCO)
Carbon monoxide diffusing capacity of the lung (DLCO) is a measurement to assess the lungs' ability to transfer gas from inspired air to the bloodstream. Its measurement uses carbon monoxide to calculate the pulmonary diffusion capacity. The most common method is the standard single-breathe diffusing capacity test. It is expressed in mmol/(min*kPa) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Carbon monoxide transfer coefficient (KCO=DLCO/Va)
KCO is CO transfer coefficient, usually written as DLCO/Va, which indicates the efficiency of CO transfer by alveoli. In other words, it is the diffusion capacity of carbon monoxide for each unit of the alveolar volume. The most common method is the standard single-breathe diffusing capacity test. It is expressed in mmol/(min*kPa*L) and as a percentage (%) of the expected value.
Measured: through study completion, an average of 2 year
Alveolar ventilation (Va)
Alveolar ventilation is amount of contributing alveolar units measured by tracer gas. It expressed in liters (L).
Measured: through study completion, an average of 2 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2023
- Study start3 Jul 2023
- Primary completion1 May 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung DiseaseStudies of the same condition, open and under way.
- More trials run by Gazi UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gazi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Meral Boşnak Güçlü, Gazi University
- Investigators
- Nazire Nur YILDIZ, M.Sc., Study chair, Gazi UniversityMeral BOŞNAK GÜÇLÜ, Prof. Dr., Study director, Gazi UniversityRiad BEJTA, Pt., Principal investigator, Gazi UniversityNilgün YILMAZ DEMİRCİ, Assoc. Prof., Principal investigator, Gazi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05916404
- Sponsor's protocol ID
- Gazi University-58
- Status last verified
- Aug 2026
- First submitted
- 29 Apr 2023
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Effects of Upper Extremity Aerobic Exercise Training on Oxygen Consumption, Muscle Oxygenation and Physical Activity in Patients With Interstitial Lung Disease
- ClinicalTrials.gov ID
- NCT05916404
- Acronym / sponsor ID
- Gazi University-58
- Conditions
- Interstitial Lung Disease
- Keywords
- Interstitial Lung Disease, Upper Extremity, Aerobic Exercise, Oxygen Consumption, Physical Activity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Gazi UniversityUniversity, hospital or other
- Study start
- 3 Jul 2023 (actual)
- Primary completion
- 1 May 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 23 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Severe dyspnea, cough, fatigue, restrictive type ventilation disorder, decreased pulmonary function, impaired gas exchange, decreased cardiovascular function and exercise intolerance are frequently encountered findings in patients with interstitial lung disease. It was demonstrated exercise training has beneficial effects in patients with interstitial lung disease. However, no study investigated the effects of upper extremity aerobic exercise training on outcomes in patients with interstitial lung disease.
Detailed description
Interstitial lung diseases (ILD) are a heterogeneous group of diseases that cause significant mortality and morbidity worldwide. As a result of the chronic inflammatory process in this disease, structural and mechanical pulmonary disorders develop, which are considered the main causes of deterioration in cardiopulmonary functions. Interstitial lung patients have a decrease in both static and dynamic lung volumes and carbon monoxide diffusing capacity (DLCO). As a result of this pathological mechanism, effort dyspnea and an increase in exercise intolerance occur. Therefore, individuals with ILD tend to avoid activities that increase shortness of breath, resulting in decreased physical activity levels and an increased sedentary lifestyle. Individuals whose functional exercise capacities are also limited due to this vicious circle become more dependent in their daily living activities. In addition, peripheral muscle dysfunction is another important factor that causes exercise intolerance in individuals with all chronic lung diseases, including ILD. One of the most important mechanisms triggering peripheral muscle dysfunction in ILD is hypoxia which develops with desaturation. Hypoxia, which causes an increase in oxidative stress, is one of the factors that can cause muscle dysfunction. It has been reported that upper extremity exercise capacity and functional performance are low in individuals with advanced ILD, and it has been stated that upper extremity exercise training may be beneficial in these patients.
However, the effects of upper extremity aerobic exercise training have not been investigated in the literature in patients with ILD. In this context, the primary aim of our study is to investigate the effects of upper extremity interval aerobic exercise training applied to patients with ILD on oxygen consumption, muscle oxygenation, and physical activity level. The secondary aim of the study is to determine the effects of this training on upper extremity functional exercise capacity, respiratory functions, pulmonary diffusion capacity, respiratory and peripheral muscle strength, inspiratory muscle endurance, dyspnea, fatigue, quality of life, sleep quality, anxiety, and depression. For this purpose, our study was planned as a randomized, controlled, three-blind (investigators, patient, and analyzer) prospective study. According to the block randomization result, at least 21 patients with a diagnosis of ILD will be included in the training and control groups.
The training group will be given upper extremity interval aerobic exercise training with arm ergometer for 30-45 minutes 3 days a week for 6 weeks, and the control group will not be given any training during the study. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
All assessments will be completed in two days, before and after six weeks of training.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Training Group | Experimental | Other: Upper extremity high-intensity interval aerobic exercise trainingThe training group will receive upper extremity high-intensity interval aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks. |
| Control Group | Sham comparator | Other: Control GroupThe control group will not be given any training for 6 weeks during the study period. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosed with ILD according to ATS/ERS criteria,
- Aged between 18-75 years,
- No pulmonary infection during the last month,
- Patients who volunteer to participate in the study
Key exclusion criteria (11 listed)
- Patients with,
- Body mass index >35 kg/m2,
- An acute pulmonary exacerbation within the last 4 weeks, have an acute upper or lower respiratory tract infection,
- Presence of obstructive pulmonary disease,
- Serious neurological, neuromuscular, orthopedic, or other diseases affecting physical functions,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Upper extremity high-intensity interval aerobic exercise trainingHigh-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate. In case of desaturation (<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient. | Other | Training Group |
| Control GroupThe control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation. | Other | Control Group |
Primary outcome
Oxygen consumption
Time frame: through study completion, an average of 2 year
Maximal exercise capacity will be assessed with symptom limited cardiopulmonary exercise test on a treadmill at a progressively increasing speed and grade. Oxygen consumption will be measured during the test.
Muscle oxygenation
Time frame: through study completion, an average of 2 year
Before the cardiopulmonary exercise test and the 6-minute pegboard and ring test (6-PBRT), during and after the tests the muscle oxygenation will be measured by using a near-infrared spectroscopy device. Oxygenation of the quadriceps muscle during the cardiopulmonary exercise test, and deltoid muscle during the 6-PBRT will be evaluated. For this purpose, the sensor will be placed at the midpoint of the dominant side muscles.
Physical activity level
Time frame: through study completion, an average of 2 year
Physical activity level will be evaluated with a multi-sensor activity device. Multisensor metabolic holter device by detecting the three-dimensional movements of patients; It provides data on total energy expenditure (joules/day), active energy expenditure (joules/day), physical activity duration (min/day), average MET (MET/day), number of steps (steps/day), time spent lying down (min/day). The device will be attached to the non-dominant arms of the patients, and they will be told to wear it for 5 consecutive days, remove the device only during the bath, and reinsert it in the same area after the bath. The average of the parameters of the current four days will be taken and analyzed with the "BodyMedia SenseWear® 7.0 Software" program using the age, gender, body weight and height information of the patients.
19 secondary outcomes
Respiratory muscle strength
Time frame: through study completion, an average of 2 year
Peripheral muscle strength
Time frame: through study completion, an average of 2 year
Upper extremity functional exercise capacity
Time frame: through study completion, an average of 2 year
Dyspnea perception
Time frame: through study completion, an average of 2 year
Fatigue
Time frame: through study completion, an average of 2 year
Life Quality
Time frame: through study completion, an average of 2 year
Sleep Quality
Time frame: through study completion, an average of 2 year
Anxiety and Depression
Time frame: through study completion, an average of 2 year
Modified Borg scale
Time frame: through study completion, an average of 2 year
Energy expenditure
Time frame: through study completion, an average of 2 year
Inspiratory muscle endurance
Time frame: through study completion, an average of 2 year
Forced expiratory volume exhaled in the first second (FEV1)
Time frame: through study completion, an average of 2 year
Forced vital capacity (FVC)
Time frame: through study completion, an average of 2 year
FEV1/FVC ratio
Time frame: through study completion, an average of 2 year
Peak expiratory flow (PEF)
Time frame: through study completion, an average of 2 year
Forced mid-expiratory flow rate (FEF25-75%)
Time frame: through study completion, an average of 2 year
Diffusion capacity for carbon monoxide (DLCO)
Time frame: through study completion, an average of 2 year
Carbon monoxide transfer coefficient (KCO=DLCO/Va)
Time frame: through study completion, an average of 2 year
Alveolar ventilation (Va)
Time frame: through study completion, an average of 2 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Interstitial Lung Disease
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Single-Cell Sequencing Analysis of Radiation Pneumonitis Signals In Patients Treated For Cancer With Radiotherapy
Radiation Pneumonitis
RecruitingPhase 2
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Fibrotic Interstitial Lung Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nazire Nur YILDIZ, M.Sc. study chair
Gazi University
Meral BOŞNAK GÜÇLÜ, Prof. Dr. study director
Gazi University
Riad BEJTA, Pt. principal investigator
Gazi University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Upper extremity high-intensity interval aerobic exercise training in people with Interstitial Lung Disease, run by Gazi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oxygen consumption (time frame: through study completion, an average of 2 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.